These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 16772535

  • 1. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E.
    CMAJ; 2006 Jul 04; 175(1):29. PubMed ID: 16772535
    [No Abstract] [Full Text] [Related]

  • 2. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep 04; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH, Donnelly C.
    Mt Sinai J Med; 2009 Apr 04; 76(2):198-203. PubMed ID: 19306385
    [No Abstract] [Full Text] [Related]

  • 4. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M.
    Pediatrics; 2007 Jan 04; 119(1):154-5. PubMed ID: 17200281
    [No Abstract] [Full Text] [Related]

  • 5. ADHD drugs and cardiovascular risk.
    Rappley MD, Moore JW, Dokken D.
    N Engl J Med; 2006 May 25; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract] [Full Text] [Related]

  • 6. [Medication for ADHD and the risk of cardiovascular mortality].
    Kalverdijk LJ, Buitelaar JK, van der Gaag RJ.
    Ned Tijdschr Geneeskd; 2006 Oct 14; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
    [No Abstract] [Full Text] [Related]

  • 7. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery.
    Pediatrics; 2008 Aug 14; 122(2):451-3. PubMed ID: 18676566
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J, Wong KK, O'Connell C, Warren AE.
    Pediatrics; 2008 Oct 14; 122(4):e828-34. PubMed ID: 18829780
    [Abstract] [Full Text] [Related]

  • 9. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 10. Stimulant medications and attention deficit-hyperactivity disorder.
    Cohen AL, Jhung MA, Budnitz DS.
    N Engl J Med; 2006 May 25; 354(21):2294-5. PubMed ID: 16723627
    [No Abstract] [Full Text] [Related]

  • 11. ADHD drugs and cardiovascular risk.
    Nissen SE.
    N Engl J Med; 2006 Apr 06; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract] [Full Text] [Related]

  • 12. To box OR NOT TO box.
    Newstadt M.
    J Ky Med Assoc; 2006 Aug 06; 104(8):344-5. PubMed ID: 16939037
    [No Abstract] [Full Text] [Related]

  • 13. ADHD drugs and cardiovascular risk.
    Anders T, Sharfstein S.
    N Engl J Med; 2006 May 25; 354(21):2296-8; author reply 2296-8. PubMed ID: 16723628
    [No Abstract] [Full Text] [Related]

  • 14. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec 25; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 15. Attention-deficit/hyperactivity disorder psychopharmacology for college students.
    Staufer WB, Greydanus DE.
    Pediatr Clin North Am; 2005 Feb 25; 52(1):71-84, viii. PubMed ID: 15748925
    [Abstract] [Full Text] [Related]

  • 16. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul 28; 50(1291):60. PubMed ID: 18654112
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL, American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee, American Heart Association Council on Cardiovascular Nursing.
    Circulation; 2008 May 06; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract] [Full Text] [Related]

  • 18. ADHD black box warning: how concerned should we be?
    Cruz R, Kutscher EC.
    S D Med; 2007 Feb 06; 60(2):63, 65. PubMed ID: 17390569
    [No Abstract] [Full Text] [Related]

  • 19. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV, Wilens TE.
    J Clin Psychiatry; 2007 Feb 06; 68 Suppl 11():15-22. PubMed ID: 18307377
    [Abstract] [Full Text] [Related]

  • 20. Addictive drugs still best option for attention deficit disorder.
    Basu P.
    Nat Med; 2006 Apr 06; 12(4):374. PubMed ID: 16598272
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.